Chou Chun, Martin Gregory L, Perera Gayani, Awata Junya, Larson Amy, Blanton Robert, Chin Michael T
Department of Medicine, Tufts University School of Medicine, Boston, MA, United States.
Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United States.
Front Cardiovasc Med. 2023 Jun 26;10:1223244. doi: 10.3389/fcvm.2023.1223244. eCollection 2023.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder affecting 1 in 500 people in the general population. Characterized by asymmetric left ventricular hypertrophy, cardiomyocyte disarray and cardiac fibrosis, HCM is a highly complex disease with heterogenous clinical presentation, onset and complication. While mutations in sarcomere genes can account for a substantial proportion of familial cases of HCM, 40%-50% of HCM patients do not carry such sarcomere variants and the causal mutations for their diseases remain elusive. Recently, we identified a novel variant of the alpha-crystallin B chain () in a pair of monozygotic twins who developed concordant HCM phenotypes that manifested over a nearly identical time course. Yet, how promotes the HCM phenotype remains unclear. Here, we generated mice carrying the knock-in allele and demonstrated that hearts from these animals exhibit increased maximal elastance at young age but reduced diastolic function with aging. Upon transverse aortic constriction, mice carrying the allele developed pathogenic left ventricular hypertrophy with substantial cardiac fibrosis and progressively decreased ejection fraction. Crossing of mice with a frame-shift model of HCM did not potentiate pathological hypertrophy in compound heterozygotes, indicating that the pathological mechanisms in the model are independent of the sarcomere. In contrast to another well-characterized variant (R120G) which induced Desmin aggregation, no evidence of protein aggregation was observed in hearts expressing despite its potent effect on driving cellular hypertrophy. Mechanistically, we uncovered an unexpected protein-protein interaction between CRYAB and calcineurin. Whereas CRYAB suppresses maladaptive calcium signaling in response to pressure-overload, the R123W mutation abolished this effect and instead drove pathologic NFAT activation. Thus, our data establish the allele as a novel genetic model of HCM and unveiled additional sarcomere-independent mechanisms of cardiac pathological hypertrophy.
肥厚型心肌病(HCM)是最常见的遗传性心血管疾病,在普通人群中,每500人就有1人患病。HCM的特征是左心室不对称肥厚、心肌细胞排列紊乱和心脏纤维化,是一种临床表现、发病和并发症具有异质性的高度复杂疾病。虽然肌节基因突变可解释相当一部分HCM家族病例,但40%-50%的HCM患者不携带此类肌节变异,其疾病的致病突变仍不清楚。最近,我们在一对同卵双胞胎中发现了αB晶状体蛋白(CRYAB)的一种新变异,他们出现了一致的HCM表型,且在几乎相同的时间进程中表现出来。然而,CRYAB如何促进HCM表型仍不清楚。在这里,我们培育了携带CRYAB敲入等位基因的小鼠,并证明这些动物的心脏在年轻时表现出最大弹性增加,但随着年龄增长舒张功能降低。在进行主动脉缩窄手术后,携带CRYAB等位基因的小鼠出现了病理性左心室肥厚,并伴有大量心脏纤维化,射血分数逐渐降低。将携带CRYAB等位基因的小鼠与HCM的移码模型杂交,并未增强复合杂合子的病理性肥厚,这表明CRYAB模型中的病理机制独立于肌节。与另一种特征明确的CRYAB变异体(R120G)诱导结蛋白聚集不同,尽管CRYAB对驱动细胞肥大有显著作用,但在表达CRYAB的心脏中未观察到蛋白质聚集的证据。从机制上讲,我们发现了CRYAB与钙调神经磷酸酶之间意外的蛋白质-蛋白质相互作用。CRYAB可抑制压力过载时的适应性钙信号传导,而R123W突变消除了这种作用,反而导致病理性核因子活化T细胞(NFAT)激活。因此,我们的数据确立了CRYAB等位基因为HCM的一种新遗传模型,并揭示了心脏病理性肥厚的其他独立于肌节的机制。